The main purpose of the Developmental Research Program (DRP) of the Pacific Northwest (PNW) Prostate Cancer SPORE is to support innovative translational prostate cancer (PC) research pilot projects aimed at reducing the morbidity and mortality due to PC and at improving the survival and quality of life of PC patients. During the initial funding of the DRP, substantial progress has been made in the development and implementation of this unique and successful research program. During the first four years of the DRP, 46 pilot project proposals were submitted and 19 projects were funded (total of $798,100.00 direct funding). Ten publications and 7 grants have resulted to date from the DRP. For this continuation grant, the DRP program will continue to provide a mechanism to quickly respond to new translational research opportunities that may develop within the SPORE environments of participating institutions: Vancouver General Hospital (VGH) Prostate Centre in Vancouver, British Columbia, Canada;the University of Washington (UW), the Fred Hutchinson Cancer Research Center (FHCRC), and the Institute for Systems Biology (ISB) in Seattle, WA;and, Oregon Health Sciences University (OHSU) in Portland, OR. Support provided by the DRP will continue to allow innovative pilot projects to be initiated, with the expectation that the projects will mature sufficiently so that they can successfully compete for additional funding from sources either within or outside the SPORE grant. This program also attracts more senior investigators with diverse scientific expertise and new investigators into translational PC research.
The specific aims for the DRP are: 1) Solicit innovative, translational prostate cancer research study proposals for pilot funding on an annual basis; 2) Convene a panel of experts to provide rigorous scientific review of pilot study proposals following NIH guidelines for selection of the most promising research projects; 3) Provide pilot study funding for 1-2 years for the most innovative investigator-initiated ideas for research in all areas of prostate cancer research (including etiology, prevention, diagnosis, biological mechanisms, genetics, and treatment) with a special emphasis on projects that address issues relevant to advancing knowledge of disease aggressiveness or metastasis;and, 4) Allow the SPORE leadership to target funds to specific areas that are especially likely to advance the translational research goals of the PNW prostate cancer SPORE.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA097186-10
Application #
8330642
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
2013-08-31
Budget Start
2011-09-08
Budget End
2012-08-31
Support Year
10
Fiscal Year
2011
Total Cost
$184,960
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Dai, James Y; Wang, Bo; Wang, Xiaoyu et al. (2018) Vigorous physical activity is associated with metastatic-lethal progression in prostate cancer and differential tumor DNA methylation in the CRACR2A gene. Cancer Epidemiol Biomarkers Prev :
Mateo, Joaquin; Cheng, Heather H; Beltran, Himisha et al. (2018) Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study. Eur Urol 73:687-693
Lim, Daniel M; Gulati, Roman; Aleshin-Guendel, Serge et al. (2018) Undetectable prostate-specific antigen after short-course androgen deprivation therapy for biochemically recurrent patients correlates with metastasis-free survival and prostate cancer-specific survival. Prostate :
Sehrawat, Archana; Gao, Lina; Wang, Yuliang et al. (2018) LSD1 activates a lethal prostate cancer gene network independently of its demethylase function. Proc Natl Acad Sci U S A 115:E4179-E4188
FitzGerald, L M; Zhao, S; Leonardson, A et al. (2018) Germline variants in IL4, MGMT and AKT1 are associated with prostate cancer-specific mortality: An analysis of 12,082 prostate cancer cases. Prostate Cancer Prostatic Dis 21:228-237
Lee, Chung C W; Munuganti, Ravi Shashi Nayana; Peacock, James W et al. (2018) Targeting Semaphorin 3C in Prostate Cancer With Small Molecules. J Endocr Soc 2:1381-1394
Mostaghel, Elahe A (2018) Alternative Acts: Oncogenic Splicing of Steroidogenic Enzymes in Prostate Cancer. Clin Cancer Res :
Zhao, Shanshan; Leonardson, Amy; Geybels, Milan S et al. (2018) A five-CpG DNA methylation score to predict metastatic-lethal outcomes in men treated with radical prostatectomy for localized prostate cancer. Prostate :
Uo, Takuma; Plymate, Stephen R; Sprenger, Cynthia C (2018) The potential of AR-V7 as a therapeutic target. Expert Opin Ther Targets 22:201-216
Bello, Thomas; Gujral, Taranjit S (2018) KInhibition: A Kinase Inhibitor Selection Portal. iScience 8:49-53

Showing the most recent 10 out of 400 publications